SEC Filing Summary: Amedica Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed on November 7, 2014, reporting events occurring on November 6, 2014. The registrant is Amedica Corporation (not Sintx Technologies, Inc., as noted in the metadata request). The filing details the entry into a material definitive agreement involving a bridge loan financing.
Key Financial Metrics and Transaction Details
- Loan Amount: $1,000,000 bridge loan from Hampshire MedTech Partners, II, L.P.
- Interest Rate: 15% per annum, accruing from the agreement date but payable at maturity.
- Maturity Date: The earlier of the third business day following a qualified secondary offering (minimum $10 million gross proceeds) or December 17, 2014.
- Commitment Fee: $75,000 payable by the Maturity Date.
- Legal Expenses: Reimbursement of up to $30,000 for the lender's attorneys' fees.
- Security: Secured by substantially all assets of the Company and its subsidiary, subordinate to existing senior secured debt held by Hercules Technology III, LP.
- Use of Proceeds: General corporate purposes.
Material Changes and Equity Issuances
The Company issued a "Closing Bridge Warrant" to the lender to purchase up to 267,380 shares of common stock at an exercise price of $1.87 per share. This warrant includes a price protection provision: if a secondary offering occurs on or before May 6, 2015, at a price below $1.87, the exercise price will be reduced to match the offering price. The warrant expires on November 5, 2019.
Additionally, the agreement mandates the issuance of "Additional Bridge Warrants" for every 30-day period the loan remains unpaid after the Maturity Date. The number of shares and exercise price for these additional warrants are based on the lowest closing stock price in the preceding 30 days. Total shares issuable under all warrants are capped at 19.99% of the outstanding common stock as of the closing date.
Management Commentary, Risks, and Contingencies
To facilitate this transaction, the Company obtained necessary waivers from existing creditors:
- Hercules Technology Waiver: Allowed the Company to enter the bridge loan without triggering a default under its existing senior secured obligations.
- Magna Waiver: Amended terms of unsecured senior convertible notes held by MG Partners II Ltd. (an affiliate of Magna), allowing the new security interest and waiving Magna's right to participate as a lender.
Risks: The loan carries a high interest rate (15%) and a significant commitment fee. If the loan is not repaid by the Maturity Date, the Company faces dilution through Additional Bridge Warrants calculated at the lowest recent stock price. The agreement includes standard covenants limiting indebtedness, liens, and asset sales, with a default interest rate of up to 18% per annum.
Investor Verification Checklist
- Verify the Company's ability to secure a qualified secondary offering of at least $10 million before December 17, 2014, to avoid immediate repayment or warrant dilution.
- Review the impact of the 19.99% cap on total warrant issuances relative to current outstanding shares.
- Confirm the status of the Company's existing senior debt with Hercules Technology and the terms of the Magna convertible notes.
- Assess the liquidity position given the $75,000 commitment fee and potential legal expense reimbursements due at maturity.
- Examine the "Additional Bridge Warrants" mechanism to understand potential dilution scenarios if the loan extends beyond the Maturity Date.